Baidu
map

JAMA Neurol:帕金森综合征中突触核蛋白病明显多于tau蛋白病

2013-07-15 sunight dxy

以帕金森综合征起病的人群中突触核蛋白病和tau蛋白病的发病频率及分布情况的资料知之甚少,而这对卫生保健规划制定和临床研究有重要影响。来自梅奥临床研究中心的Rodolfo Savica等医师研究了不同帕金森综合征及相关蛋白病的发病率及不同类型的分布情况,发表在2013年7月的JAMA Neurology杂志上,结果显示帕金森综合征相关的蛋白病发病率随年龄急剧增加,男性发病率高于女性。突触核蛋白病临床

以帕金森综合征起病的人群中突触核蛋白病和tau蛋白病的发病频率及分布情况的资料知之甚少,而这对卫生保健规划制定和临床研究有重要影响。来自梅奥临床研究中心的Rodolfo Savica等医师研究了不同帕金森综合征及相关蛋白病的发病率及不同类型的分布情况,发表在2013年7月的JAMA Neurology杂志上,结果显示帕金森综合征相关的蛋白病发病率随年龄急剧增加,男性发病率高于女性。突触核蛋白病临床数量明显高于tau蛋白病。

该研究使用明尼苏达州Olmsted地区罗切斯特流行病学项目的病历连锁系统筛选所有与帕金森综合征相关的病例,时间跨度为1991年1月1日至2005年12月31日,共15男。由一位运动障碍学专家详细阅读每例患者的病例资料,使用特异的临床标准评价帕金森综合征的类型及可能蛋白病类型。评价明尼苏达州Olmsted地区人口的帕金森综合征和不同蛋白病的发病特点。

在542例帕金森综合征患者中,409 (75.5%)归于蛋白病类,其中389例(71.8%)患者推测为突触核蛋白病,264例为帕金森病(占所有病例的48.7%)。突触核蛋白的发病率为每100000人年21.0,且随着年龄增高急剧增加。tau蛋白病的总体发病率为1.1(20例患者),最主要的tau蛋白病为进行性核上性麻痹(16例患者)。36例患者为药物诱发的帕金森综合征(6.6%),11例为血管性帕金森综合征(2.0%),1例(0.2%)帕金森综合征为肌萎缩侧所硬化,1例(0.2%)为继发于手术的帕金森综合征,最后84例(15.5%)仍无法分类。在各类帕金森综合征中,男性发病率明显高于女性。最终65例脑活检中,有53例(81.5%)脑活检结果与临床诊断相符合。

该研究显示与帕金森综合征相关的蛋白病发病率随年龄急剧增加,男性发病率高于女性。突触核蛋白病临床数量明显高于tau蛋白病。活检结果证实临床对蛋白病的推测。该研究或可指导卫生保健规划的制定,同时也提供临床研究的方向。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
    2014-01-09 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1986079, encodeId=afe919860e99e, content=<a href='/topic/show?id=4fff62153ee' target=_blank style='color:#2F92EE;'>#核蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62153, encryptionId=4fff62153ee, topicName=核蛋白)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Mon Jul 29 14:45:00 CST 2013, time=2013-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1665721, encodeId=9f991665e2142, content=<a href='/topic/show?id=de2a485385f' target=_blank style='color:#2F92EE;'>#帕金森综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48538, encryptionId=de2a485385f, topicName=帕金森综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43d925986347, createdName=12498f1em16(暂无昵称), createdTime=Fri Feb 07 09:45:00 CST 2014, time=2014-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999317, encodeId=c79d199931e84, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Jan 09 08:45:00 CST 2014, time=2014-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430396, encodeId=e0d514303962a, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478768, encodeId=c35114e876881, content=<a href='/topic/show?id=76efe555021' target=_blank style='color:#2F92EE;'>#突触#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75550, encryptionId=76efe555021, topicName=突触)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5207457717, createdName=ms691033630344116, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509246, encodeId=11ee15092464f, content=<a href='/topic/show?id=19791e14471' target=_blank style='color:#2F92EE;'>#Tau#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17144, encryptionId=19791e14471, topicName=Tau)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55c610090940, createdName=szhvet, createdTime=Wed Jul 17 02:45:00 CST 2013, time=2013-07-17, status=1, ipAttribution=)]
    2013-07-17 szhvet

相关资讯

NEJM:下丘脑刺激有助于改善早期帕金森症状

  法国和德国研究人员合作开展的一项随机试验显示,在药物治疗基础上加用下丘脑刺激,不仅可改善早期帕金森病患者的生活质量和轻度左旋多巴诱导的运动并发症,还可以减少后续的运动残疾。   主要作者W.M.M. Schüpbach博士和EARLYSTIM(对于早期帕金森病患者进行深部脑刺激的对照试验)研究组的同事指出,已知这种联合治疗对晚期帕金森病患者有益,而这一新发现提示“神经刺激可能作为较当前

ANN NEUROL:吃青椒可预防帕金森氏症

吃青椒可以预防帕金森氏症? 许多小朋友可能都跟卡通人物蜡笔小新一样不敢吃青椒,把它当成最可怕的食物, 不过国外有研究发现,吃青椒可以预防帕金森氏症,华盛顿大学研究指出,每个礼拜吃两次茄科蔬菜的人,像是青椒甜椒辣椒番茄茄子,可以预防帕金森氏症罹患的机率可降至少三成。 研究认为,是因为基底核会受到烟碱的刺激,可以增加大脑多巴胺的含量,有助降低帕金森式风险。 与帕金森相关的拓展阅读:

NEJM:脑刺激配合药物治疗早期帕金森更优

  近日,《新英格兰医学杂志》发表了一项研究表明,早期帕金森患者脑神经部刺激和药物治疗同时进行的疗效,优于仅接受药物治疗的患者。   研究人员对251名病程4年以上的早期帕金森患者进行研究,研究结果表明,对于较早期的帕金森疾病,在患者的严重运动并发症没有出现之前,脑部神经刺激优于单独药物治疗。研究人员建议临床医生不要单一依靠传统的药物来对早期帕金森患者进行治疗。与帕金森相关的拓展阅读: NEJ

帕金森可在细胞间传播

  了解疾病的进展机制是找到治疗方法来阻止它的第一步,也是最重要的步骤之一。如阿尔茨海默氏症等脑退化性疾病就是这种情况。经过几年渐进性的研究,现在来自宾夕法尼亚大学Perelman医学院的研究人员将重要的步骤拼凑到了一起,揭示了帕金森氏病(PD)在细胞之间传播并导致神经细胞死亡的机制。   他们的研究还揭示了一个广义的概念:这种类型的疾病过程是其他神经退行性疾病,如阿尔茨海默氏症、亨廷顿氏病、进

默沙东旗下帕金森病药物Preladenant研发失败

默沙东宣布旗下帕金森病试验药物Preladenant研发失败,因为这款药物在后期临床试验中没能显示有多大希望。 公司表示,Preladenant用于帕金森病治疗的三项独立III期临床研究数据与安慰剂数据相比,不能提供这款药物有任何疗效的证据。因此,默沙东表示正采取措施停止这些研究的扩展性研究,并不再寻求这款药物的上市许可申请。 默沙东在2009年以41亿美元收购先灵葆雅时获得这款腺苷A2A受体

Nat Commun:新型化合物可有效降低帕金森疾病的发病进程

2012年10月25日来自美国西北大学的研究者开发出了一种新型的化合物家族,其可以有效减缓帕金森疾病的病情发展。相关研究成果刊登于10月23日的国际杂志Nature Communications上。 帕金森疾病是第二大常见的神经变性疾病,是由于大脑多巴胺神经元死亡所引发的疾病,可以使得患者颤栗、僵硬以及行动困难,当前适应症的疗法并不能减缓病情的发展。研究者所开发的新型化合物,通过以运输钙至多巴胺

Baidu
map
Baidu
map
Baidu
map